SanBio
4592.TTSE GROWTHPharmaceutical
Financials · Consolidated
| Fiscal year ended | 2026-01 | 2025-01 | 2024-01 | 2023-01 | 2022-01 | 2021-01 |
|---|---|---|---|---|---|---|
| Operating income | −¥3.8bn | −¥3.5bn | −¥4.5bn | −¥7.9bn | −¥6.6bn | — |
| Ordinary income | −¥4.3bn | −¥3.0bn | −¥2.8bn | −¥4.7bn | −¥4.6bn | −¥6.5bn |
| Net income (owners) | −¥3.8bn | −¥2.9bn | −¥2.6bn | −¥5.6bn | −¥4.7bn | −¥3.4bn |
| Total assets | ¥15.6bn | ¥3.4bn | ¥5.0bn | ¥7.0bn | ¥5.5bn | ¥13.3bn |
| Net assets / equity | ¥13.6bn | ¥1.8bn | ¥2.8bn | ¥4.4bn | ¥2.0bn | ¥8.3bn |
| Operating cash flow | −¥3.8bn | −¥3.6bn | −¥4.8bn | −¥7.4bn | −¥6.5bn | −¥5.2bn |
| EPS (basic) | ¥-52.55 | ¥-41.86 | ¥-40.48 | ¥-95.99 | ¥-90.33 | ¥-65.38 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 7
| Period | Form | Figures |
|---|---|---|
| 2024-02-01 → 2024-04-30 | Quarterly Q1 | 38 figures · EDINET |
| 2023-02-01 → 2023-10-31 | Quarterly Q3 | 40 figures · EDINET |
| 2023-02-01 → 2023-07-31 | Quarterly Q2 | 64 figures · EDINET |
| 2023-02-01 → 2023-04-30 | Quarterly Q1 | 38 figures · EDINET |
| 2022-02-01 → 2022-10-31 | Quarterly Q3 | 40 figures · EDINET |
| 2022-02-01 → 2022-07-31 | Quarterly Q2 | 64 figures · EDINET |
| 2022-02-01 → 2022-04-30 | Quarterly Q1 | 38 figures · EDINET |
21 more reports are still being processed.